Abstract
Aztreonam pharmacokinetics were assessed in seven patients treated for urinary (n = 6) or lower respiratory (n = 1) tract infections. Each patient was studied twice, at the beginning and end of therapy (7 to 10 days). The patients enrolled had normal to moderately impaired renal function; a good correlation (r2 = 0.90) between serum aztreonam clearance (CL) and creatinine clearance (CLCR) was observed (mean CL/CLCR ratio = 1.11). CL ranged from 21.6 to 121 ml/min per 70 kg, and the half-life ranged from 1.6 to 8.9 h. The mean steady-state volume of distribution (0.16 +/- 0.05 [standard deviation] liter/kg) approximated the extracellular fluid volume. Protein binding of aztreonam in serum (mean, 30%) was lower than that reported in healthy adults. CL increased significantly from the first to the last day of the study, probably reflecting increasing renal function. After multiple dosing (1 g every 8 h), no significant accumulation of aztreonam was observed. Overall, the disposition of aztreonam is comparable in infected and noninfected subjects, and dosing adjustments in patients with renal impairment should be facilitated by the good correlation between CL and CLCR.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- Craig W. A., Welling P. G. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1977 Jul-Aug;2(4):252–268. doi: 10.2165/00003088-197702040-00002. [DOI] [PubMed] [Google Scholar]
- Mihindu J. C., Scheld W. M., Bolton N. D., Spyker D. A., Swabb E. A., Bolton W. K. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1983 Aug;24(2):252–261. doi: 10.1128/aac.24.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pilkiewicz F. G., Remsburg B. J., Fisher S. M., Sykes R. B. High-pressure liquid chromatographic analysis of aztreonam in sera and urine. Antimicrob Agents Chemother. 1983 Jun;23(6):852–856. doi: 10.1128/aac.23.6.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reidenberg M. M., Drayer D. E. Effects of renal disease upon drug disposition. Drug Metab Rev. 1978;8(2):293–302. doi: 10.3109/03602537808993789. [DOI] [PubMed] [Google Scholar]
- Riggs D. S., Guarnieri J. A., Addelman S. Fitting straight lines when both variables are subject to error. Life Sci. 1978 Apr 3;22(13-15):1305–1360. doi: 10.1016/0024-3205(78)90098-x. [DOI] [PubMed] [Google Scholar]
- Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
- Shand D. G. Biological determinants of altered pharmacokinetics in the elderly. Gerontology. 1982;28 (Suppl 1):8–17. doi: 10.1159/000212568. [DOI] [PubMed] [Google Scholar]
- Swabb E. A., Singhvi S. M., Leitz M. A., Frantz M., Sugerman A. Metabolism and pharmacokinetics of aztreonam in healthy subjects. Antimicrob Agents Chemother. 1983 Sep;24(3):394–400. doi: 10.1128/aac.24.3.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swabb E. A., Sugerman A. A., McKinstry D. N. Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother. 1983 Jan;23(1):125–132. doi: 10.1128/aac.23.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swabb E. A., Sugerman A. A., Platt T. B., Pilkiewicz F. G., Frantz M. Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother. 1982 Jun;21(6):944–949. doi: 10.1128/aac.21.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]